Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.

L Ceresoli, G; A Zucali, P; Mencoboni, M; Botta, M; Grossi, F; Cortinovis, D; Zilembo, N; Ripa, C; Tiseo, M; G Favaretto, A; Soto-Parra, H; De Vincenzo, F; Bruzzone, A; Lorenzi, E; Gianoncelli, L; Ercoli, B; Giordano, L; Santoro, A

doi:10.1038/bjc.2013.368

Public

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.

Shared by NobleBlocks on Aug 6, 2013 • 12:00 AM UTC

Authors:

G L Ceresoli

P A Zucali

M Mencoboni

Abstract

BACKGROUND: The aim of this open label phase II study (NCT00407459) was to assess the activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined with pemetrexed and carboplatin in patients with previously untreated, unresectable malignant pleural mesothelioma (MPM). MET...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!